Eπίπεδα οστεοποντίνης σε ασθενείς με καρκίνο πνεύμονα

Postgraduate Thesis uoadl:1314777 192 Read counter

Unit:
Κατεύθυνση Καρκίνος Πνεύμονα: Σύγχρονη Κλινικοεργαστηριακή Προσέγγιση και Έρευνα
Library of the School of Health Sciences
Deposit date:
2012-07-11
Year:
2011
Author:
Ραμφίδης Βασίλειος
Supervisors info:
Καθηγητής Κωνσταντίνος Συρίγος (επιβλέπων), Καθηγητής Κ. Γεννατάς, Διδάκτωρ Ιωάννης Μούντζιος
Original Title:
Eπίπεδα οστεοποντίνης σε ασθενείς με καρκίνο πνεύμονα
Languages:
Greek
Summary:
Introduction: Biological markers with predictive and prognostic capacity in non
small-cell lung cancer are currently lucking. A multifunctional protein called
osteopontin has been shown to be linked to tumorigenesis, disease progression
and development of metastases
Purpose: The aim of this study was to investigate the relationship between
plasma levels of OPN and clinical outcomes in patients with NSCLC and bone
metastases.
Patients and Methods: Plasma OPN levels were measured by ELISA in 39 patients
before and after treatment with three to six cycles of platinum-based
chemotherapy and zoledronic acid. Baseline OPN levels and their changes after
treatment were correlated with tumor characteristics, performance status (PS),
tumor response, bone pain and other clinicopathological parameters.
Results: Higher baseline OPN levels correlated with higher T (P<0,001) and N
(P=0,009), based on TNM staging system but did not correlate with PS (P=0,598).
When examined as a continuous variable, OPN maintained its association with TNM
staging. Patients with increased post-treatment OPN levels as compared to
baseline ones were significantly more likely to have progressive disease
according to RECIST criteria (P<0,001). Furthermore, reduction of OPN levels
correlated with decrease of bone pain due to skeletal metastases (P<0,001). No
associations were observed between OPN levels and haematological parameters
such as hemoglobin, platelets, bone alkaline phosphatase and serum calcium.

Conclusions: Plasma levels of OPN are associated with various tumor
characteristics, response to treatment with chemotherapy and zoledronic acid
and skeletal-related pain. The results of this pilot study, if confirmed in
larger cohorts, suggest a potential utility of OPN as prognostic biomarker in
NSCLC
Keywords:
Ostepontin, Lung cancer, Bone metastases, Skeletal-related pain, Prognostic value
Index:
No
Number of index pages:
0
Contains images:
Yes
Number of references:
93
Number of pages:
114

document.pdf
1 MB
File access is restricted only to the intranet of UoA.